The Forum in collaboration with Boehringer Ingelheim is making available the RESIST datasets from the pivotal tipranavir trials. The RESIST trials are international randomized studies of ritonavir boosted tipranavir treatment of the HIV-1 infections of three drug-class experienced patients. This endeavor is a first with regard to a public-private collaborative approach to improving our understanding and interpretation of drug resistance and its consequences. It provides an opportunity for advancing the field of interpretation of complex and highly dimensional datasets, benefiting the drug development, drug regulation, clinical research and clinical application sectors within the HIV community.
Academic and government collaborators are invited to submit proposals (Appendix B) for analysis for review by the FCHR HIV Drug Resistance Project Review Committee. If approved and following receipt of a signed agreement, Collaborators will have access to the RESIST Datasets as described in Appendix A. All results obtained by Collaborators will be reviewed by the FCHR Review Committee and a publication plan developed jointly between Collaborators and the FCHR Review Committee.
The full request for proposals can be accessed by clicking here.
Appendix A can be accessed by clicking here.
Appendix B can be accessed by clicking here.
The terms of the model agreement can be accessed by clicking here.